Optimus Pharma gets nod for phase 3 trials of Molnupiravir capsule
Updated:
Updated:
Share Article
AAA
Drug-maker Optimus Pharma on Wednesday said it received approval of the Drugs Controller General of India (DCGI) to conduct Phase III clinical trials for Molnupiravir capsule on mild and moderate COVID-19 patients.
As per the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of five days and the total study duration will be a maximum of 29 days from randomisation, the release said.
Capsule enhances online CRM platform with Microsoft 365 integration
News provided by
Share this article
Share this article
MANCHESTER, United Kingdom, May 14, 2021 /PRNewswire/ Capsule, the online CRM, has launched an integration with Microsoft 365 (M365), enhancing its platform with a new Microsoft Outlook add-in, Calendar integration, and Single Sign-On.
For the first time, Capsule customers using Microsoft business applications can connect their CRM to their Outlook inbox, enabling the ability to add contacts, view and manage sales opportunities, and build a complete record of interaction all stored in one place.
Duncan Stockdill, Co-Founder & CEO, Capsule
Using the Microsoft Outlook Calendar integration, Capsule customers can easily view and manage calendar events from within the CRM, without duplicating across platforms, and view all consolidated events associated with each customer to better manage new and existing relationships.
AlleyWatch
The Weekly Notable Startup Funding Report takes us on a trip across various ecosystems in the US, highlighting some of the notable funding activity in the various markets that we track. The notable startup funding rounds for the week ending 5/1/21 featuring funding details for Automox, Honorlock, and twenty-seven other rounds that you must know about.